Obesity Drug Imcivree Among Eight New Products To Win EMA Nod
Executive Summary
The European Medicines Agency today revealed the names of the latest new products it believes should be approved for use across the EU.
You may also be interested in...
Rare Diseases: European Market Access ‘Better Organized’ Than US, Says Rhythm
Rhythm is working with country-level authorities and centers of excellence in Europe to gain reimbursement and access for its obesity treatment Imcivree.
Idorsia’s Insomnia Drug Daridorexant Among 14 Hopefuls For EU Verdict
The European Medicines Agency will likely decide this week whether to recommend for pan-EU approval new treatments for insomnia, uveal melanoma, migraine and advanced prostate cancer.
EU Accelerated Assessment Tracker
Novartis is one of the latest companies to fail in its attempt to have a marketing authorization application fast-tracked at the European Medicines Agency. There was better news for BioMarin.